Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in late 2019 and spread globally, prompting an international effort to accelerate development …

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …

Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

Persistence of Antibody after mRNA-1273 Vaccination A total of 33 participants who received
both doses of the Moderna mRNA-1273 vaccine against SARS-CoV-2 had blood drawn …

Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two
100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish
vaccine-induced protective immune responses, particularly as antibody titers wane over time. …

Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine
that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (…